===
EQS-News: Affluent Medical SA / Key word(s): Miscellaneous
Affluent Medical achieves the clinical objective of the Dry pilot study in the first two patients with the Artus
artificial urinary sphincter
2024-06-18 / 17:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Affluent Medical achieves the clinical objective of the Dry pilot study in the first two patients with the Artus
artificial urinary sphincter
. Second successful implantation of the innovative Artus medical device in Krakow, Poland
. Successful activation of the Artus device in the first two patients six weeks after surgery
. Artus, an artificial sphincter adapted to the treatment of incontinence in both men and women, addresses
a substantial medical need with 400 million patients affected worldwide
Aix-en-Provence, June 18, 2024 - 5:45 PM CEST - Affluent Medical (ISIN: FR0013333077 - Ticker: AFME), a French
clinical-phase MedTech company specializing in the international development and industrialization of innovative
medical prostheses, is announcing the successful activation of its Artus medical device for the treatment of urinary
incontinence in the first two patients as part of the European pilot study, "Dry".
After the successful implantation of the Artus device in an initial patient in the Czech Republic, as reported last
March, the device has been successfully implanted in a 70-year-old man suffering from urinary incontinence in Poland by
the urologist Professor Piotr Chlosta, President of the Department of Urology of the Faculty of Medicine of
Jagiellonian University in Krakow and Head of the Clinical Department of Urology and Oncology at the University
Hospital of Krakow.
This second minimally invasive procedure confirmed the ease with which the Artus device can be prepared and implanted,
with a surgery time of 45 minutes.
The two Artus devices were successfully activated six weeks after each surgery. The safety criteria were met and both
patients expressed no discomfort using the device. A performance assessment will be carried out in the pivotal phase,
the aim being to reduce urinary leakage three months after the activation of the device.
Sébastien Ladet, Affluent Medical CEO declares: "Achieving the objectives of the pilot study on these first two
patients is a very encouraging result. It enables us to make further progress in demonstrating the safety of the
device, and to gather the first patient feedback. This step enables us to move towards our goal of ten patients in the
Dry pilot study by the end of 2024".
Urinary incontinence is a major public health problem worldwide. The pathology affects men and women alike at different
stages of their lives. It is generally more prevalent among women than men, notably among younger patients (aged 25 and
over) with disorders resulting from multiple child births or in older patients (40 and over) from prostate or bladder
cancer treatments. Urinary incontinence has a major impact on social life and mental health. Many patients develop
anxiety and depression disorders, as the pathology remains vastly taboo. According to Optima Insights, the global
market for medical devices for the treatment of urinary incontinence (including slings, neurostimulators and artificial
sphincters) is expected to reach USD4.3 billion by 2027, growing annually 11% between 2019 and 2027.

About Affluent Medical
Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader
in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary
incontinence, which currently affects one in four adults.
Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore
critical physiological functions. The product candidates developed by the Company are currently all in clinical
studies.
Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies,
the Company's ambition is to gradually commercialize its products early 2026.
For more information, visit www.affluentmedical.com
Contacts:
AFFLUENT MEDICAL SEITOSEI -- ACTIFIN
Financial communications / press relations

Sébastien LADET               Ghislaine GASPARETTO / Jennifer JULLIA 
Chief Executive Officer       +33 (0)6 21 10 49 24 / +33 (0)1 56 88 11 19 
investor@affluentmedical.com  ghislaine.gasparetto@seitosei-actifin.com / 

jennifer.jullia@seitosei-actifin.com

PRIMATICE                     MC SERVICES AG 
Media relations France        Media relations Europe 
Thomas ROBOREL de CLIMENS     Caroline BERGMANN / Kirsten RÜHL 
+33 (0)6 78 12 97 95          +49 (0)211 529252 20 / +49 (0)211 529252 16 

thomasdeclimens@primatice.com affluent@mc-services.eu
===
-----------------------------------------------------------------------------------------------------------------------

2024-06-18 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

-----------------------------------------------------------------------------------------------------------------------

===

Language:     English 
Company:      Affluent Medical SA 

320 avenue Archimède - Les pléiades III Batiment B
13100 Aix-en-Provence
France

E-mail:       affluent@mc-services.eu 
Internet:     www.affluentmedical.com 
ISIN:         FR0013333077 
EQS News ID:  1927971 

End of News EQS News Service
===
1927971 2024-06-18 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1927971&application_name=news

END) Dow Jones Newswires

June 18, 2024 11:45 ET (15:45 GMT)